These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 13129388)

  • 21. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.
    White DM; Jensen MA; Shi X; Qu Zx ; Arnason BG
    Protein Expr Purif; 2001 Apr; 21(3):446-55. PubMed ID: 11281720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
    Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
    Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
    Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
    Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate.
    Torgov MY; Alley SC; Cerveny CG; Farquhar D; Senter PD
    Bioconjug Chem; 2005; 16(3):717-21. PubMed ID: 15898742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
    Meyer DL; Jungheim LN; Law KL; Mikolajczyk SD; Shepherd TA; Mackensen DG; Briggs SL; Starling JJ
    Cancer Res; 1993 Sep; 53(17):3956-63. PubMed ID: 8358723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
    Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
    Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
    Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
    Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv.
    Chowdhury PS; Vasmatzis G; Beers R; Lee B; Pastan I
    J Mol Biol; 1998 Sep; 281(5):917-28. PubMed ID: 9719644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
    Gillies SD; Wesolowski JS
    Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
    Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
    Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
    Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
    J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody.
    Santos AD; Kashmiri SV; Hand PH; Schlom J; Padlan EA
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3118s-3123s. PubMed ID: 10541352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-directed lymphocyte-activating cytokines: refolding-based preparation of recombinant human interleukin-12 and an antibody variable domain-fused protein by additive-introduced stepwise dialysis.
    Makabe K; Asano R; Ito T; Tsumoto K; Kudo T; Kumagai I
    Biochem Biophys Res Commun; 2005 Mar; 328(1):98-105. PubMed ID: 15670756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular design and construction of IL6D24-PE40KDEL, a novel recombinant interleukin6-pseudomonas exotoxin fusion protein, having targeted cytotoxicity for leukemias expressing interleukin6 receptors].
    Zheng LY; Xi YZ; Kong FH; Cui JW; Liang F; Liu N; Sun YY; Guo SQ
    Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(14):1246-50. PubMed ID: 12930640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix-assisted refolding of single-chain Fv- cellulose binding domain fusion proteins.
    Berdichevsky Y; Lamed R; Frenkel D; Gophna U; Bayer EA; Yaron S; Shoham Y; Benhar I
    Protein Expr Purif; 1999 Nov; 17(2):249-59. PubMed ID: 10545273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.
    Goel A; Colcher D; Baranowska-Kortylewicz J; Augustine S; Booth BJ; Pavlinkova G; Batra SK
    Cancer Res; 2000 Dec; 60(24):6964-71. PubMed ID: 11156397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
    Heinis C; Alessi P; Neri D
    Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.
    Kügler M; Stein C; Schwenkert M; Saul D; Vockentanz L; Huber T; Wetzel SK; Scholz O; Plückthun A; Honegger A; Fey GH
    Protein Eng Des Sel; 2009 Mar; 22(3):135-47. PubMed ID: 19188138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
    Bosslet K; Czech J; Hoffmann D
    Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.